

## FREQUENTLY ASKED QUESTIONS ABOUT RADICAVA ORS® (EDARAVONE)

### What is RADICAVA ORS?

RADICAVA ORS® (edaravone) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that currently has no cure and can progress rapidly without treatment.<sup>1,2</sup> RADICAVA ORS is the oral formulation of edaravone, the active ingredient in RADICAVA® (edaravone), an FDA-approved intravenous (IV) treatment shown to help slow the loss of physical function in people with ALS.<sup>1,3</sup>

You should not receive RADICAVA or RADICAVA ORS if you are allergic to edaravone or any of the ingredients of these products. Serious hypersensitivity and sulfite allergic reactions can occur. See **Important Safety Information** on pages 6-7 of this document.

### How do I know if RADICAVA ORS is right for me?

You should work with your doctor to determine if RADICAVA ORS is an appropriate treatment option for you.

### How is RADICAVA ORS different from the IV formulation of RADICAVA?

RADICAVA and RADICAVA ORS are versions of the same drug, edaravone, which has been shown in clinical trials to slow the loss of physical function in ALS, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) – a validated, questionnaire-based tool for evaluating ALS disease progression and loss of physical function over time.<sup>1,3,4</sup>

The difference between RADICAVA and RADICAVA ORS is how they are taken. RADICAVA is taken through an IV infusion and RADICAVA ORS is taken orally, or via feeding tube, in a 5 mL dose, providing a flexible administration option to people with ALS.<sup>1</sup>

You should work with your doctor to determine if RADICAVA ORS is right for you.

### What will RADICAVA ORS do for people with ALS? How meaningful of a treatment is it?

RADICAVA ORS is an oral formulation of edaravone, the active ingredient in RADICAVA, an FDA-approved IV treatment for ALS that has been shown to slow the loss of physical function by 33% (approximately one-third) vs. placebo, as measured by the ALSFRS-R.<sup>1,3</sup> Specifically, a pivotal, Phase 3 clinical trial demonstrated that at 24 weeks (about 6 months), people who did not receive RADICAVA declined more rapidly in physical function, having lost an average of 2.49 points more than those who received RADICAVA.<sup>1,3</sup> For people with ALS, losing or keeping a single point on the ALSFRS-R may have a significant impact. The most common adverse



*RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.*

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

events that occurred in greater than 10 percent of people treated with RADICAVA were bruising (contusion), problems walking (gait disturbance) and headache.<sup>1,3</sup>

RADICAVA ORS may be an important new oral treatment option in helping people with ALS live with the disease. ALS can progress rapidly, and while people with ALS experience varying rates of progression, slowing the loss of physical function is incredibly important.

### **If I'm currently on the IV formulation, should I switch to RADICAVA ORS?**

You should work with your doctor to determine if RADICAVA ORS is right for you.

Please note, the IV formulation will still be available to people with ALS, and treatment will not cease if you are currently taking the medication and choose to or are advised by your doctor to remain on the treatment.

### **What is the recommended dose of RADICAVA ORS and how it is administered? Do I need to go to a clinic or my doctor's office to get the medication?**

RADICAVA ORS, the oral form of edaravone, is approved to be taken as a 5 mL dose that can be taken orally or via feeding tube, offering the flexibility of oral treatment.<sup>1</sup> With appropriate instruction from your doctor, RADICAVA ORS may take only a few minutes to administer on treatment days.

RADICAVA ORS should be taken in the morning on an empty stomach. You should stop eating at bedtime. Do not eat or drink anything but water within eight hours after a high fat meal, four hours after a low-fat meal, or within two hours after a caloric supplement. Wait at least one hour after taking your medication before eating or drinking anything except water. For initial treatment, RADICAVA ORS is taken once daily for 14 days followed by 14 consecutive days off. For subsequent cycles, RADICAVA ORS is taken on 10 of 14 days, followed by 14 consecutive days off each month. Taking RADICAVA ORS daily can occur on any 10 days in the 14-day treatment period.<sup>1</sup>

Patients should store RADICAVA ORS at room temperature and protected from light. It requires shaking but does not require water or additional mixing steps. Discard 15 days after opening bottle or if unopened 30 days from date of shipment indicated on the carton pharmacy label.<sup>1</sup>

For more information on how to administer RADICAVA ORS, please refer to the Instructions For Use with the [Prescribing Information](#) at [www.RADICAVA.com](http://www.RADICAVA.com).

### **What data formed the basis for the FDA approval?**



*RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.*

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

The FDA approval of RADICAVA ORS is supported by several clinical trials evaluating the oral and IV formulations of edaravone.

RADICAVA ORS is an oral form of edaravone, the active ingredient in RADICAVA, an FDA-approved IV treatment for ALS that has been shown to slow the loss of physical function by 33% (approximately one-third) vs. placebo, as measured by the ALSFRS-R.<sup>1,3</sup> Specifically, a Phase 3 clinical trial (Study MCI186-19) evaluating 137 people with ALS was conducted with RADICAVA versus placebo. That study demonstrated that at 24 weeks (about 6 months), study participants who did not receive RADICAVA declined more rapidly in physical function, having lost an average of 2.49 points more than those who received RADICAVA.<sup>1,3</sup> The most common adverse events that occurred in greater than 10 percent of people treated with RADICAVA were bruising (contusion), problems walking (gait disturbance) and headache.<sup>1,3</sup> Since 1995, RADICAVA is the only FDA-approved treatment for ALS with positive results from a Phase 3 trial despite more than 125 clinical trials from 2008-2019.<sup>1,3,5</sup>

In addition, RADICAVA ORS was evaluated across seven Phase 1 clinical trials, as well as a global Phase 3, 24-week trial demonstrating the safety and tolerability profile of the treatment in 185 people with ALS.<sup>1,6</sup> Fatigue was observed in 7.6% of patients taking RADICAVA ORS.<sup>1,6</sup>

### What were the safety results?

RADICAVA ORS offers people with ALS a similar safety profile as RADICAVA, the IV formulation. In a clinical trial for RADICAVA the most common adverse events that occurred in greater than 10% of people treated with RADICAVA were bruising (contusion), problems walking (gait disturbance) and headache.<sup>1,3</sup>

The safety and tolerability of RADICAVA ORS was demonstrated in a global Phase 3 trial evaluating 185 people with ALS for 24 weeks (about 6 months).<sup>1,6</sup> Fatigue was observed in 7.6% of study participants.<sup>1,6</sup> Fewer than 6% of people discontinued RADICAVA ORS due to study side effects.<sup>1,6</sup> Approximately 1% of people discontinued RADICAVA ORS due to gastrointestinal side effects (diarrhea and trouble swallowing).<sup>1,6</sup> Other reasons for discontinuation (1%) included respiratory failure and muscular weakness.<sup>1,6</sup>

RADICAVA and RADICAVA ORS may cause serious side effects. These include:

Hypersensitivity (allergic) reactions: Hypersensitivity reactions have happened in people receiving RADICAVA and can happen after your infusion is finished.

Sulfite allergic reactions: RADICAVA and RADICAVA ORS contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium



*RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.*

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

bisulfite can also cause less severe asthma episodes in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma.

Tell your healthcare provider (HCP) right away or go to the nearest emergency room if you have any of the following symptoms: hives; swelling of the lips, tongue, or face; fainting; breathing problems; wheezing; trouble swallowing; dizziness; itching; or an asthma attack (in people with asthma).

Your HCP will monitor you during treatment to watch for signs and symptoms of all of the serious side effects and allergic reactions.

Please see additional **Important Safety Information** on pages 6-7 of this document.

### Is there anyone who should not receive RADICAVA ORS?

RADICAVA ORS is contraindicated in people with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions and anaphylactic reactions have been reported in people receiving RADICAVA.<sup>1</sup>

### Can I receive RADICAVA ORS if I'm also taking riluzole or other medications?

Patients considering RADICAVA ORS should talk to their doctor about all treatment decisions. In clinical trials, riluzole was given along with RADICAVA in more than 90% of patients. There are no known drug-to-drug interactions with RADICAVA ORS.<sup>1</sup> Tell your doctor about all medications you are taking.

## Accessing RADICAVA ORS Treatment

### How do I get RADICAVA ORS?

We anticipate RADICAVA ORS will be available to people with ALS in the coming weeks; however, there are steps you can take now to be able to access RADICAVA ORS when it becomes available.

- Like other FDA-approved medications, RADICAVA ORS requires a prescription from your doctor. Schedule an appointment with your doctor and determine if it is an appropriate treatment for you.
- Once RADICAVA ORS is available and you have received a prescription, work with your doctor to complete a Benefits Investigation and Enrollment Form to understand your insurance coverage and determine when to start treatment.
- Once the form is submitted, a **JourneyMate Support Program™** Insurance & Access Specialist will reach out to help you understand the steps to accessing your RADICAVA



RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

ORS prescription, including investigating your health insurance coverage, health plan benefits, specialty pharmacy options and financial support options.

- For more information, patients and caregivers can call 1-866-684-7737 or visit [radicava.com/journeymate](http://radicava.com/journeymate).

### How much will RADICAVA ORS cost me? Will it be covered by my insurance?

We understand how important RADICAVA ORS is to people with ALS. Therefore, MTPA continues to invest in financial assistance programs that directly lower out-of-pocket costs for eligible patients.

Once you receive a prescription for RADICAVA ORS, work with your doctor to complete a Benefits Investigation and Enrollment Form, which starts the process of investigating whether your health plan covers the medication. Upon receiving the signed form, a **JourneyMate Support Program™** Insurance & Access Specialist will then work with you to help determine whether you meet the eligibility criteria for any of MTPA's financial support options.

Patients who have specific questions about their insurance coverage should contact their insurer directly.

### What do I do if I don't have insurance?

Our Patient Assistance Program provides support for people who are in financial need and have no insurance. Patients who meet the eligibility requirements may be able to receive RADICAVA ORS at no charge for up to two years. These requirements include:

- The patient must be a citizen or a permanent resident of the U.S. or its territories, and reside in the U.S. or its territories.
- The patient's income must not exceed five times the Federal Poverty Level based on household size (Federal Poverty Level Guidelines are available at <https://aspe.hhs.gov/poverty-guidelines>). Please visit [www.RADICAVA.com](http://www.RADICAVA.com) for full Program details.

Once you and your doctor have decided RADICAVA ORS is right for you and have submitted a complete Benefits Investigation and Enrollment Form, the **JourneyMate Support Program™** Insurance and Access Specialist will complete an eligibility determination for the Patient Assistance Program.

### How does the JourneyMate Support Program™ work?

No matter where you are in your ALS journey – from diagnosis to treatment – the **JourneyMate Support Program™** gives you the understanding, answers and resources to help you move forward. Experienced program team members are trained to address your educational needs and provide you with personalized answers and resources for living with ALS.



RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

A go-to resource in the **JourneyMate Support Program™** for general information about ALS and RADICAVA ORS is an ALS Resource Specialist. An Insurance & Access Specialist can help you understand insurance coverage, financial support options, site of care and specialty pharmacy options. Once you're prescribed RADICAVA ORS, an ALS Clinical Educator can provide personal education to you and your family regarding RADICAVA ORS and will also provide resources throughout your treatment. This program is here to supplement the resources that your doctor provides.

For more information, patients and caregivers can call 1-866-684-7737 or visit [radicava.com/journeymate](http://radicava.com/journeymate).

*The **JourneyMate Support Program™** offers educational support and resources for patients who are considering or have already been prescribed a Mitsubishi Tanabe Pharma America, Inc. (MTPA) product. An ALS Clinical Educator is an educational resource for patients who have been prescribed an MTPA product. An ALS Clinical Educator is provided by MTPA and VMS and is not affiliated with or provided by a doctor. An ALS Clinical Educator does not provide medical advice. The program does not provide medical advice and does not take the place of a patient's doctor. All questions about a condition, diagnosis, or treatment should be referred to the patient's doctor. If a patient has a medical emergency, they should call 911. Adverse events or product complaints should be reported by calling 1-888-292-0058.*

### What if I have clinical questions about RADICAVA ORS, who can I contact?

Through our **JourneyMate Support Program™**, an ALS Clinical Educator can provide personal education to you and your family once you're prescribed RADICAVA ORS and will also provide resources throughout your treatment.

Please keep in mind, an ALS Clinical Educator cannot provide medical advice. Please contact your doctor for all questions specific to your condition, diagnosis or treatment.

### IMPORTANT SAFETY INFORMATION

**Do not receive RADICAVA (edaravone) or RADICAVA ORS (edaravone) if you are allergic to edaravone or any of the ingredients in RADICAVA and RADICAVA ORS.**

**Before you take RADICAVA or RADICAVA ORS, tell your healthcare provider about all of your medical conditions, including if you:**

- have asthma.
- are allergic to other medicines.
- are pregnant or plan to become pregnant. It is not known if RADICAVA or RADICAVA ORS will harm your unborn baby.



RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

- are breastfeeding or plan to breastfeed. It is not known if RADICAVA or RADICAVA ORS passes into your breastmilk. You and your healthcare provider should decide if you will receive RADICAVA or RADICAVA ORS or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

### What are the possible side effects of RADICAVA and RADICAVA ORS?

RADICAVA and RADICAVA ORS may cause serious side effects, including hypersensitivity (allergic) reactions and sulfite allergic reactions.

- Hypersensitivity reactions have happened in people receiving RADICAVA or taking RADICAVA ORS and can happen after your medicine has been given.
- RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe asthma episodes in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma.
- Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: hives; swelling of the lips, tongue, or face; fainting; breathing problems; wheezing; trouble swallowing; dizziness; itching; or an asthma attack (in people with asthma).

Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects and allergic reactions.

The most common side effects include bruising (contusion), problems walking (gait disturbance), and headache.

These are not all the possible side effects of RADICAVA or RADICAVA ORS. **Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058.**

### INDICATION

RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).

For more information, including full [Prescribing Information](#), please visit [www.RADICAVA.com](http://www.RADICAVA.com).

---

<sup>1</sup> RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022.



*RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.*

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

---

<sup>2</sup> “Amyotrophic Lateral Sclerosis (ALS) Fact Sheet.” National Institute of Neurological Disorders and Stroke, National Institutes of Health, June 2013, <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet>.

<sup>3</sup> Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 2017;16(7):505-512.

<sup>4</sup> Rutkove SB., et al. Clinical measures of disease progression in amyotrophic lateral sclerosis. *Neurotherapeutics.* 2015;12(2):384-393.

<sup>5</sup> Wong C, Stavrou M, Elliott E, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. *Brain Commun.* 2021;3(4): fcab242

<sup>6</sup> ClinicalTrials.gov. 2019. Safety Study of Oral Edaravone Administered in Subjects With ALS. <https://clinicaltrials.gov/ct2/show/NCT04165824>.



*RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.*

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

For U.S. Use Only

CP-OE-US-0231 05/22